Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral difelikefalin for pruritus in advanced chronic kidney disease (Hungary)
2022-000149-34Phase 3Terminated
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Nov 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and chronic kidney disease-associated pruritus (CKD-aP) comparing Oral difelikefalin with Placebo (2 arms). Started Nov 2022; status: terminated.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on 2022-000149-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000149-34.